A ptose Biosciences’ tuspetinib boosted response rates when used in combination with standard of care (SoC) in a Phase I/II ...

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating ...

MRD and Relapse in Patients With AML Gail J. Roboz, MD; Roland B. Walter, MD, PhD Disclosures August 17, 2022 0 ...

2. Jeyakumar D, O’Brien S. Minimal residual disease in acute myeloid leukemia. JAMA Onc. Published online October 8, 2020. doi: 10.1001/jamaoncol.2020.4599.

Dynamic measurable residual disease (MRD) can be used to optimize postremission treatment for young patients with acute myeloid leukemia (AML). The researchers used the South China Hematology ...

In acute myeloid leukemia (AML), assessment of minimal residual disease (MRD) by flow cytometry (flow MRD) after induction and consolidation therapy has been shown to provide independent ...

Based on this analysis, the investigators concluded that MRD after induction chemotherapy identifies patients with NPM1-mutated AML who benefit from ASCT in first remission. Further, after second ...

In acute myeloid leukemia (AML) that is in complete remission, minimal residual disease (MRD) is presumed to be present, though not morphologically evident. Advances in diagnostics now permit the ...

Achievement of minimal residual disease negativity appeared associated with superior DFS and OS among patients with acute myeloid leukemia, according to results of a meta-analysis published in ...

Minimal residual disease, a benchmark for identifying patients who are at risk for relapse, is typically done using flow cytometry. Next-generation sequencing now refines the process with ...

In the article that accompanies this commentary, Luskin and Stone 4 grapple with these and other questions and provide a comprehensive review of modalities for MRD detection in patients with AML ...

Leukemia - Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis ...